Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 7/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | QDPR | P09417 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169400 | 0.79 | SIGMAR1 (0.56) | SIGMAR1HTR2CQDPRKDM4EALDH1A1 | |
| SCHEMBL30454304 | 0.79 | SIGMAR1 (0.56) | SIGMAR1HTR2CQDPRKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4002469 | 0.77 | HTR2C (0.58) | SIGMAR1HTR2CQDPRKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL17667435 | 0.77 | HTR2C (0.58) | SIGMAR1HTR2CQDPRKDM4EALDH1A1 | |
| SCHEMBL4789657 | 0.77 | SIGMAR1 (0.64) | SIGMAR1HTR2CHRH3QDPRKDM4E | |
| Hydrochloric Acid SCHEMBL25208309 | 0.73 | HTR2C (0.50) | SIGMAR1HTR2CHRH3QDPRKDM4E | |
| Hydrochloric Acid SCHEMBL30307693 | 0.73 | HTR2C (0.50) | SIGMAR1HTR2CHRH3QDPRKDM4E | |
| SCHEMBL171391 | 0.73 | HTR6 (0.47) | SIGMAR1HTR2CHRH3QDPRKDM4E | |
| SCHEMBL15001445 | 0.72 | SIGMAR1 (0.41) | SIGMAR1HTR2CHRH3QDPRKDM4E | |
| SCHEMBL171607 | 0.72 | HTR2C (0.59) | SIGMAR1HTR2CHRH3QDPRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008015271-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
| WO-2007066103-A1 | PYRIMIDINE DERIVATIVES AS CLASS I PI3K INHIBITOR | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | SIGMAR1 243/4885HTR2C 222/4885HRH3 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.